Hanx Biopharmaceuticals (Wuhan) , Ltd. PEG Ratio

Hanx Biopharmaceuticals (Wuhan) , Ltd. posts a PEG ratio of 424.74. That is above the Healthcare sector average of 0.46. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a PEG ratio near 0.46 is typical. Hanx Biopharmaceuticals (Wuhan) , Ltd.'s 424.74 is higher that level. That is roughly 91525.3% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Hanx Biopharmaceuticals (Wuhan) , Ltd.'s PEG ratio of 424.74 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for 3378.HK's PEG ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 0.46), and (3) consistency with growth and profitability. This page covers the first two; Hanx Biopharmaceuticals (Wuhan) , Ltd.'s other metric pages and overview cover the third.

Judging Hanx Biopharmaceuticals (Wuhan) , Ltd. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in PEG ratio easier to interpret. Start with 424.74 here, then scan peer and history charts to see if the gap is persistent.